Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy.
Authors: Rivera-Caravaca JM, Esteve-Pastor MA, Camelo-Castillo A, Ramírez-Macías I, Lip GYH, Roldán V, Marín F Abstract INTRODUCTION: Oral anticoagulants (OAC) reduce stroke/systemic embolism and mortality risks in atrial fibrillation (AF). However, there is an inherent bleeding risk with OAC, where intracranial hemorrhage (ICH) is the most feared, disabling, and lethal complication of this therapy. Therefore, the optimal management of OAC-associated ICH is not well defined despite multiple suggested strategies. AREAS COVERED: In this review, the authors describe the severity and risk factors for OAC-associ...
Source: Expert Opinion on Pharmacotherapy - July 15, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants.
Conclusion and Relevance: The HAS-BLED, HEMORR2HAGES, RIETE, and CHEST scores were found to have sufficient diagnostic accuracy for predicting risk of major bleeding in our study population; however, no score was identified as having an AUC greater than 0.7. Caution may be considered when utilizing these scores for patients on DOACs. PMID: 32517484 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 8, 2020 Category: Drugs & Pharmacology Authors: Tchen S, Ryba N, Patel V, Cavanaugh J, Sullivan JB Tags: Ann Pharmacother Source Type: research

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects
ConclusionsThis study revealed the pharmacokinetic characteristics and good safety profile of dabigatran in healthy Chinese subjects.
Source: European Journal of Drug Metabolism and Pharmacokinetics - May 29, 2020 Category: Drugs & Pharmacology Source Type: research

A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation
Conclusion Many residents with non-valvular AF and significant risk of stroke were not receiving oral anticoagulation despite a lack of documented reason for non-prescribing. Non-vitamin K antagonists were widely prescribed but dosing of these agents could still be improved. There remains a need to improve anticoagulant prescribing for aged care residents and optimise stroke prevention in this population.
Source: International Journal of Clinical Pharmacy - April 13, 2020 Category: Drugs & Pharmacology Source Type: research

Vitamin D and vascular disease.
Abstract Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Vitamin D deficiency has been identified as a potential risk factor for a number of diseases unrelated to the classical skeletal pathophysiology, such as cancer and CVD, but the effects of vitamin D supplementation are less clear. Purpose of this narrative review is to discuss the evidence suggesting an association between vitamin D status and CVD as well as the results of supplementation studies. Vitamin D deficiency has been associated with CVD risk factors such as hypertension, dyslipidemia and diabetes mellitus as well...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Gouni-Berthold I, Berthold HK Tags: Curr Vasc Pharmacol Source Type: research

Drug treatment strategies for osteoporosis in stroke patients.
Authors: Hsieh CY, Sung SF, Huang HK Abstract Introduction: Osteoporosis and subsequent fractures are well-recognized complications of stroke. However, drug treatment strategies for osteoporosis after stroke have been rarely discussed in the current guidelines for the management of stroke or osteoporosis.Areas covered: The authors review the epidemiology, characteristics, pathophysiology, and risk prediction of post-stroke osteoporosis and fractures. Then they provide an overview of existing evidence regarding drug treatment strategies for osteoporosis in stroke patients. They also review the effects on bone minera...
Source: Expert Opinion on Pharmacotherapy - March 11, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists
ConclusionsThis retrospective observational study found a similar efficacy between DOAC and VKA agents in patients with LV thrombi (70.6% vs. 71.5%); however, when the thrombus remains, VKAs are still the standard of care as it is possible to control INR levels (3 –4) with them.
Source: Clinical Drug Investigation - March 5, 2020 Category: Drugs & Pharmacology Source Type: research

Use of a bioengineered antioxidant in mouse models of metabolic syndrome.
Conclusions: PEG-HCC can improve some parameters of disease in these models and this may be due to a resulting increase in peripheral insulin sensitivity. However, additional studies are needed to elucidate how PEG-HCCs are producing these effects. PMID: 31937152 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - January 17, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Cost-effectiveness of dabigatran compared with rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China.
Abstract PURPOSE: In China, dabigatran and rivaroxaban are the only approved non-vitamin K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this article was to assess the cost-effectiveness of dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in Chinese patients with AF from the perspective of the Chinese health care system. METHODS: A Markov model was constructed to estimate the cost-effectiveness of dabigatran versus rivaroxaban. Clinical events were modeled for a lifetime horizon, based on clinical efficacy data from indirect treatment...
Source: Clinical Therapeutics - January 9, 2020 Category: Drugs & Pharmacology Authors: Dong SJ, Wu B, Zhai SD, Zhang YJ, Chu YB, Gupta P, Li YH Tags: Clin Ther Source Type: research

Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Abstract PURPOSE: The use of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and bioprosthetic heart valve is still controversial. The aim of this study was to compare the tolerability and effectiveness of treatment with DOACs versus vitamin K antagonists (VKAs) in patients with AF and a bioprosthetic heart valve in clinical practice. METHODS: Data for this study were sourced from the multicenter, prospectively maintained AF Research Database (NCT03760874), which includes all patients with AF undergoing follow-up at participating centers through outpatient visits every 3-6 months....
Source: Clinical Therapeutics - November 13, 2019 Category: Drugs & Pharmacology Authors: Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, Parisi V, Scotti A, Nigro G, Golino P, D'Onofrio A Tags: Clin Ther Source Type: research

All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System
Background: Many patients with heart failure (HF) are treated with warfarin or non-vitamin K oral anticoagulants (NOACs). Randomized outcome-driven comparisons of different anticoagulant strategies in HF are lacking. Data from international, government-mandated registries may be useful in understanding the real-life use of various anticoagulants and how they are linked to outcomes. Study Question: To assess 2015 annual all-cause mortality, myocardial infarction, and stroke rates co-reported for warfarin and NOACs in subjects with and without HF in the US Food and Drug Administration Adverse Event Reporting System (FAE...
Source: American Journal of Therapeutics - November 1, 2019 Category: Drugs & Pharmacology Tags: Original Research Source Type: research

Mortality risk in atrial fibrillation: the role  of aspirin, vitamin K and non-vitamin K antagonists
Conclusion Non vitamin K oral anticoagulants are   associated with a higher risk on all-cause mortality, particularly in men and in patients with higher stroke risk.
Source: International Journal of Clinical Pharmacy - October 7, 2019 Category: Drugs & Pharmacology Source Type: research

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome and percutaneous coronary intervention.
Authors: Gumprecht J, Domek M, Lip GY Abstract Introduction: The non-vitamin K antagonist oral anticoagulants (NOACs) are changing the landscape for stroke prevention in atrial fibrillation (AF) and prevention or treatment of venous thromboembolism (VTE). In patients with AF and concomitant acute coronary syndrome (ACS), the treatment regimen of combined NOACs and P2Y12 inhibitors is gaining popularity. Areas covered: The authors conducted a review of studies published in the last 10 years regarding safety evaluation and effectiveness of apixaban for the treatment of AF and ACS, both alone and in combination with d...
Source: Expert Opinion on Drug Safety - October 4, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review
Conclusions: The use of DOACs is a reasonable alternative to vitamin K antagonists in AF patients with CHADS2 score ≥3, advanced age, and HF. The RI constitutes a useful, additional tool to facilitate clinicians in choosing DOACs or warfarin in particular category of AF patients.
Source: Frontiers in Pharmacology - September 18, 2019 Category: Drugs & Pharmacology Source Type: research

Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients
Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
Source: International Journal of Clinical Pharmacy - September 13, 2019 Category: Drugs & Pharmacology Source Type: research